Kamada Stock Discussion

$Kamada (KMDA.US)$
Kamada Announces a $25 Million 3-Year Contract for Supply of KAMRAB® and VARIZIG® in Latin America
Kamada (NASDAQ: KMDA) has secured a significant $25 million contract for supplying KAMRAB® and VARIZIG® in Latin America over a three-year period from 2025-2027. This contract with an international organization reinforces Kamada's position in the specialty plasma-derived field.
KAMRAB is used for post-exposure prevention of rabies infection, while VARIZIG is indicated for pos...

$Kamada (KMDA.US)$ Reuters
1 min ago
Kamada Announces a $25 Million 3-Year Contract for Supply of Kamrab® and Varizig® in Latin America

$Kamada (KMDA.US)$ Kamada: FDA Agrees With Error Control Rate Change for Phase 3 Trial for Alpha-1 Antitrypsin >KMDA.TA.TV
Dow Jones· 4 mins ago

$Kamada (KMDA.US)$ Press Release: Kamada Reports Strong First Quarter 2024 Financial Results With Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises Full-Year Financial Guidance

$Kamada (KMDA.US)$ Honestly expecting/expected more here! the company had great earnings! They are overall profitable and now this binding agreement thats worth 180 million over the first 4 years! yup expected/looking for more?

$Kamada (KMDA.US)$ Kamada Announces its Largest Commercial Agreement; A Strategic Engagement with Kedrion for U.S. Distribution of KEDRAB® including $180 Million of Revenues Over First Four Years 1 MINUTE AGO, 7:00 AM EST VIA GLOBENEWSWIRE

$Kamada (KMDA.US)$ reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.03 by 100 percent. This is a 500 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $37.93 million which beat the analyst consensus estimate of $37.54 million by 1.06 percent. This is a 17.75 percent increase over sales of $32.22 million the same period last year.